Prevalence and Predictors of Neoadjuvant Therapy for Stage IIIA Non-Small Cell Lung Cancer in the National Cancer Database: Importance of Socioeconomic Status and Treating Institution

被引:18
|
作者
Sher, David J. [1 ]
Liptay, Michael J. [2 ]
Fidler, Mary Jo [3 ]
机构
[1] Rush Univ, Med Ctr, Dept Radiat Oncol, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Dept Cardiothorac Surg, Chicago, IL 60612 USA
[3] Rush Univ, Med Ctr, Sect Med Oncol, Chicago, IL 60612 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2014年 / 89卷 / 02期
关键词
RANDOMIZED-TRIAL; PHASE-II; PREOPERATIVE CHEMOTHERAPY; RACIAL-DIFFERENCES; RADIATION-THERAPY; ONCOLOGY-GROUP; RADIOTHERAPY; SURGERY; CHEMORADIATION; CARCINOMA;
D O I
10.1016/j.ijrobp.2014.01.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The optimal locoregional therapy for stage IIIA non-small cell lung cancer (NSCLC) is controversial, with definitive chemoradiation therapy (CRT) and neoadjuvant therapy followed by surgery (NT-S) serving as competing strategies. In this study, we used the National Cancer Database to determine the prevalence and predictors of NT in a large, modern cohort of patients. Methods and Materials: Patients with stage IIIA NSCLC treated with CRT or NT-S between 2003 and 2010 at programs accredited by the Commission on Cancer were included. Predictors were categorized as clinical, time/geographic, socioeconomic, and institutional. In accord with the National Cancer Database, institutions were classified as academic/research program and as comprehensive and noncomprehensive community cancer centers. Logistic regression and random effects multilevel logistic regression were performed for univariable and multivariable analyses, respectively. Results: The cohort consisted of 18,581 patients, 3,087 (16.6%) of whom underwent NT-S (10.6% induction CRT, 6% induction chemotherapy). The prevalence of NT-S was constant over time, but there were significant relative 31% and 30% decreases in pneumonectomy and right-sided pneumonectomy, respectively, over time (P trend <.02). In addition to younger age, lower T stage, and favorable comorbidity score, indicators of higher socioeconomic status were strong independent predictors of NT-S, including white race, higher income, and private/managed insurance. The type of institution (academic/research program vs comprehensive or noncomprehensive community cancer centers, odds ratio 1.54 and 2.08, respectively) strongly predicted NT-S, but treatment volume did not. Conclusions: Neoadjuvant therapy followed by surgery was an uncommon treatment approach in Commission on Cancer programs, and the prevalence of postinduction pneumonectomy decreased over time. Higher socioeconomic status and treatment at academic institutions were significant predictors of NT-S. Further research should be performed to enable a better understanding of these disparities. (C) 2014 Elsevier Inc.
引用
收藏
页码:303 / 312
页数:10
相关论文
共 50 条
  • [21] Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer
    Sher, David J.
    Fidler, Mary Jo
    Liptay, Michael J.
    Koshy, Matthew
    LUNG CANCER, 2015, 88 (03) : 267 - 274
  • [22] Treatment of stage IIIA non-small cell lung cancer
    Robinson, LA
    Wagner, H
    Ruckdeschel, JC
    CHEST, 2003, 123 (01) : 202S - 220S
  • [23] Management of stage IIIA non-small cell lung cancer (NSCLC) role of the chemotherapy
    Baudoux, Nathalie
    Friedlaender, Alex
    Addeo, Alfredo
    CURRENT CHALLENGES IN THORACIC SURGERY, 2022, 4
  • [24] Management of Stage IIIA (N2) Non-Small Cell Lung Cancer
    Gillaspie, Erin A.
    Wigle, Dennis A.
    THORACIC SURGERY CLINICS, 2016, 26 (03) : 271 - +
  • [25] Preoperative concurrent radiochemotherapy and surgery for stage IIIA non-small cell lung cancer
    Kang, MK
    Ahn, YC
    Lim, DH
    Park, K
    Park, JO
    Shim, YM
    Kim, J
    Kim, K
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2006, 21 (02) : 229 - 235
  • [26] Timing of of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer
    Gao, Sarah J.
    Corso, Christopher D.
    Wang, Elyn H.
    Blasberg, Justin D.
    Detterbeck, Frank C.
    Boffa, Daniel J.
    Decker, Roy H.
    Kim, Anthony W.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) : 314 - 322
  • [27] Neoadjuvant chemoradiation in non-small cell lung cancer
    Milleron, B.
    Girard, N.
    Gounant, V.
    Mornex, F.
    CANCER RADIOTHERAPIE, 2007, 11 (1-2): : 36 - 40
  • [28] Neoadjuvant therapy in non-small cell lung cancer
    Grant, Christopher
    Hagopian, Garo
    Nagasaka, Misako
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 190
  • [29] Combined modality therapy in Stage IIIA non-small cell lung cancer: clarity or confusion despite the highest level of evidence?
    Jeremic, Branislav
    Casas, Francesc
    Dubinsky, Pavol
    Gomez-Caamano, Antonio
    Cihoric, Nikola
    Videtic, Gregory
    Latinovic, Miroslav
    JOURNAL OF RADIATION RESEARCH, 2017, 58 (03) : 267 - 272
  • [30] Neoadjuvant chemoradiation in non-small cell lung cancer
    Girard, N.
    Hennequin, C.
    Mornex, F.
    ONCOLOGIE, 2007, 9 (06) : 475 - 481